24 results
Thumbnail

D1.136 - Allergen awareness of patients in allergology consultations at the pneumophthisiology department of the Ignace Deen University Hospital

Thumbnail

D1.134 - Mapping the Patient’s Journey Prior to Allergen Immunotherapy

Thumbnail

D1.135 - ”Bee Pollen” as a Potential Trigger for Anaphylaxis: A Case Study

Thumbnail

D1.137 - Characterization of Pana g 1, a novel allergen from Korean ginseng, Panax ginseng triggering Pollen-Food Allergy Syndrome

Thumbnail

D1.138 - IgE cross-reactivity between grass species in the presence of Japanese cedar pollen sensitization

Thumbnail

D1.139 - Staphylococcus aureus (carriage and sensitization) - is it a significant factor in allergic rhinitis?

Thumbnail

D1.144 - Global variations of IgE cross-reactivity in Cupressus allergy

Thumbnail

D1.145 - A Clinical Decision Support System (CDSS) based on Machine Learning for the diagnosis of Seasonal Allergenic Rhinitis (SAR) and patient-tailored AIT prescription

Thumbnail

D1.148 - Heterogeneity of sensitization profiles between Central and Southern European allergic patients

Thumbnail

D1.435 - Eosinophilic diseases: from nasal polyposis, eosinophilic asthma to EGPA (Eosinophilic Vasculitis with PolyAngioitis), evaluation of possible biomarkers of disease evolution

Thumbnail

D1.437 - Frequency of SNPs associated with pharmacogenetic phenotypes in Asthma in two Colombian populations

Thumbnail

D1.439 - Is allergic conjunctivitis tip of the allergic iceberg ?

Thumbnail

D1.440 - Single cell pipeline to improve immune cell annotation through comparison of multiple bioinformatic methods

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series